Stichweh Dorothee, Pascual Virginia
Baylor Institute for Immunology Research, Dallas, TX 75204, USA.
Curr Rheumatol Rep. 2005 Dec;7(6):421-6. doi: 10.1007/s11926-005-0045-4.
Although the pathogenesis of SLE remains poorly understood, there is consensus that it involves a combination of genetic, hormonal, and environmental factors. New technologies applied to genomic and gene expression studies have revealed novel gene mutations and cytokine alterations in this disease. Recently, advances in monoclonal antibodies and recombinant DNA technology have resulted in the development of new drugs to arrest disease progression and restore physiologic immune responses without major side effects. Clinical trials to test several of these novel therapies are currently underway.
尽管系统性红斑狼疮(SLE)的发病机制仍未完全明了,但人们普遍认为它涉及遗传、激素和环境因素的综合作用。应用于基因组和基因表达研究的新技术揭示了该疾病中新的基因突变和细胞因子改变。最近,单克隆抗体和重组DNA技术的进展已导致开发出能阻止疾病进展并恢复生理免疫反应且无重大副作用的新药。目前正在进行测试其中几种新疗法的临床试验。